89 results about "Imipenem" patented technology

The invention relates to a preparation method of a high-activity palladium-carbon catalyst for synthesis of imipenem antibiotics. According to the preparation method of the high-activity palladium-carbon catalyst for the synthesis of the imipenem antibiotics, ammonium chloropalladite and salts thereof are taken as precursor compounds of an active component, namely palladium, powdered activated carbon is taken as a carrier, additives such as sodium citrate are added into Pd impregnation liquid, and then the Pd impregnation liquid is absorbed onto the activated carbon in a segmenting manner and subjected to wet chemical reduction to obtain the high-activity palladium-carbon catalyst; and the catalyst is used for industrial production of the synthesis of the imipenem antibiotics.

The present invention relates to a cost effective and industrially advantageous process for the preparation of imipenem of high purity.

The invention discloses a preparation method for imipenem medicine intermediate 4AA. The preparation method comprises making 4-substituted aniline into an intermediate A, perform epoxidation on L-threonine to produce (2R, 3R)-epoxy butyric acid; enabling (2R, 3R)-epoxy butyric acid and the intermediate A to undergo a coupling reaction, obtaining an intermediate B, enabling the intermediate B to undergo a cyclization reaction, obtaining an intermediate C, enabling the intermediate C to undergo a hydroxyl protection reaction, obtaining an intermediate D, enabling the intermediate D to be oxidized to form an acetoxy group, and enabling an oxidized product to undergo an ozonation reaction, wherein G is H, F, Cl, Br, a methoxy group, oxethyl or an amino group; and R is H, straight chain alkyl of C1-C6, cyclopropyl, isopropyl, tert-butyl, a phenyl group, p-chlorophenyl, o-chlorophenyl, p-bromophenyl, o-bromophenyl, p-methoxyphenyl, o-methoxyphenyl or m-methoxyphenyl. According to the preparation method, raw materials are cheap and easy to obtain, reaction conditions are mild, the conversion rate and the yield rate are high, and the preparation method is suitable for industrial production.

The present invention relates to an improved process for the preparation of imipenem comprising reacting a bicyclo ketone precursor of the Formula II,

wherein R is a protecting group, with a phosphorohalidate in the presence of a base and a catalytic amount of dialkylaminopyridine.

The invention dislcloses the process for preparing Imipenem/Cilastatin Sodiun cryodesiccation powder preparation, which is prepared from imipenem, Cilastatin Sodium or the mixture of imipenem and Cilastatin Sodium.

According to a method for detecting the plasma protein binding rate of meropenem or imipenem by combining a liquid chromatography-mass spectrometry technology with an ultrafiltration technology, the liquid chromatography-tandem mass spectrometry detection technology is combined with the ultrafiltration technology, and the total concentration of meropenem or imipenem in plasma and the free concentration of drugs in ultrafiltrate are respectively detected. And an MOPs stabilizer is added during sample treatment, so that the problem of poor drug stability is solved, and the determination result is more accurate. The method can be used for rapidly detecting the protein binding rate of the drug at high throughput, and is particularly suitable for unstable drug molecules.

The invention discloses application of pithecellobium clypearia extracts to preparation of multi-drug resistant acinetobacter baumannii medicine. The pithecellobium clypearia extracts are prepared through the method includes the steps that pithecellobium clypearia coarse powder is extracted with water or an ethyl alcohol solution, the obtained extraction liquid is extracted with ethyl acetate, and the obtained extracts are target products. The antibacterial function of the pithecellobium clypearia extracts to multi-drug resistant acinetobacter baumannii and the sensitivity enhancing function of the pithecellobium clypearia extracts to similar antibiotics are disclosed for the first time. Tests prove that the pithecellobium clypearia extracts and imipenem or tetracycline or polymyxin B or ceftazidime or levofloxacin take effect together, and the use amount of antibiotics can be reduced by 50-87% compared with the mode that only the pithecellobium clypearia extracts are used. The pithecellobium clypearia extracts can serve as natural multi-drug resistant acinetobacter baumannii medicine or an antibiotic sensitivity-enhancing agent, and is applied to treatment of diseases caused by acinetobacter baumannii. A new means and alternative medicine are provided for solving the drug resistance problem of similar antibiotics.

The invention discloses application of ursolic acid in inhibiting growth of multi-drug-resistance enterobacter cloacae. According to a good in-vitro killing function of ursolic acid upon anthropogenic multi-drug-resistance enterobacter cloacae which resists to cefazolin, cefotaxime, aupmentn, meropenem, ofloxacin, levofloxacin, ciprofloxacin, cefoxitin, minocycline, imipenem, piperacillin, azithromycin and macrodantin, growth of multi-drug-resistance enterobacter cloacae can be inhibited, the lowest sterilization concentration is 0.6mg/mL, and the lowest antibacterial concentration is 0.3mg/mL. The invention discloses an inhibition function of the ursolic acid upon the multi-drug-resistance enterobacter cloacae, and the ursolic acid is capable of effectively alleviating or solving the drug-resistance infection problem of the multi-drug-resistance enterobacter cloacae and reducing the case fatality rate, provides new ideas for inhibiting anthropogenic multi-drug-resistance enterobacter cloacae, and has great practical significances.

The present invention generally relates to methods for treating tuberculosis in a subject comprising administering to the subject an antibiotic in conjunction with clavulanic acid or salt thereof. The antibiotic can be carbapenem (e.g., meropenem or imipenem) or cefuroxime. The present invention also relates to related pharmaceutical compositions and methods for manufacturing said pharmaceutical compositions.

The invention discloses a lipophilic compound conjugate of cell penetrating peptide and its application in antibiosis. The lipophilic compound conjugate is formed by connecting cell penetrating peptide, and a lipophilic compound connected with an amino terminal or a carboxyl terminal of the cell penetrating peptide. The lipophilic compound conjugate of antimicrobial peptide has good inhibiting and killing effects on gram positive bacteria, gram negative bacteria and fungus, so the conjugate has broad-spectrum antibacterial effect,. On inhibition of methicillin-resistant staphylococcus aureus, C12-TAT united clarithromycin has additive effect; C12-TAT united imipenem has obvious synergistic effect. On inhibition of pseudomonas aeruginosa, C16-TAT united clarithromycin has additive effect; C16-TAT united imipenem has obvious synergistic effect.

Disclosed is an imine-resistant bacillus pyocyaneus bacteriophage and its use for treating infection, wherein a stain of broad-spectrum drug-resistant bacillus pyocyaneus bacteriophage phiA392, which can effectively kill drug-resistant bacillus pyocyaneus in vivo and in vitro, the bacteriophage can decompose multiple strains of clinically segregated imipenem-resistant bacillus pyocyaneus in vivo. The invention proves the superiority and feasibility of bacteriophage as a therapeutic substance in the clinical application to the treatment of bacillus pyocyaneus resistant affection, and provides a novel therapeutic means for clinical imipenem-resistant bacillus pyocyaneus affection.

Disclosed herein is a compound of Formula II below: OH wherein R₁ is a p-nitrobenzyl or p-methoxybenzyl, group; and R₂ and R₃ may be identical to or different from each other and are each independently a C_1-6alkyl or aryl group, or a derivative thereof, and a process for preparing the compound of Formula II. Further disclosed is a process for preparing imipenem of Formula I below: by using the compound of Formula II.

The invention discloses an application of citral in inhibiting growth of multi-drug resistant enterobacter cloacae. The citral can inhibit growth of multi-drug resistant enterobacter cloacae as the citral has relatively good in vitro killing action to multi-drug resistant enterobacter cloacae resisting cefazolin, cefotaxime, augmentin, meropenem, ofloxacin, levofloxacin, ciprofloxacin, cefoxitin, minocyline, imipenem, piperacillin, azithromycin, macrodantin, sulfamethoxazole and nalidixic acid. The minimum bactericidal concentration is 1.6 mg/mL and the minimal inhibitory concentration is 1.0 mg/mL. The invention provides inhibiting action of citral to multi-drug resistant enterobacter cloacae and the citral has wide application value in the field of medicine.

The invention belongs to the technical field of medicines, more particularly relates to imipenem derivant containing sulfonyl azetidine shown in a formula (I), acceptable salts in pharmacy, easily-hydrolyzed ester and a formula (II) of a midbody thereof, wherein R<1>, R<2>, R<3>, R<4> and R<5> are defined as a specification; and the invention also relates a preparation method of the compounds andthe midbody as well as the application of the compounds in the preparation of medicines for treating and/or preventing infectious diseases.

The invention provides an imipenem and cilastatin sodium sterile powder preparation for injection and a preparation method thereof. The solubilizing effect of a pH regulator of sodium bicarbonate on imipenem is utilized; the solubility of the imipenem in a water solution is increased; antioxidants are added, so that the oxidative deterioration of the imipenem and the cilastatin sodium sterile powder preparation in production and storage processes is reduced; the use of medical auxiliary materials is reduced; the manufacturing process is simplified; the cost is reduced; meanwhile, the contents of relevant substances are reduced; the production of the stable-quality imipenem and cilastatin sodium sterile powder preparation for injection can be ensured.

The invention provides an imipenem intermediate and a preparation method thereof. The preparation method includes: uner the organic base A, adding a compound III and diphenyl chlorophosphate in an organic solvent A for reaction to obtain an intermediate IV; under the organic base B, adding cysteamine hydrochloride to the intermediate IV, and performing stirring, suction filtration, cleaning and drying after reaction to obtain an imipenem intermediate I. In the method, under the organic base C, the imipenem intermediate I and an imine side chain are added in an organic solvent D for reaction toobtain an intermediate V; the intermediate V is subjected to separation and purification, then an organic solvent E and organic base D are added, hydrogenation is performed after pH is adjusted, andthen filtration, stirring, suction filtration, cleaning and drying are performed to obtain imipenem II; with the method, shortcomings of low conversion rate and poor crystallinity of reactants due toserious accumulation of impurities, by-products and raw materials in the hydrogenation phase in the existing preparation process of the imipenem are overcome.

The invention discloses application of sanguinarine in inhibiting growth of multi-drug-resistant enterobacter horbiae. The sanguinarine has a good in-vitro killing effect on the multi-drug-resistant enterobacter horbiae of piperacillin, levofloxacin, bromgrantine, imipenem, ofloxacin, furadantin, cefathiaquine, azithromycin and naphthyridine acid, and can inhibit the growth of the multi-drug-resistant enterobacter horbiae, the minimum inhibitory concentration is 0.12 mg/mL, and the minimum bactericidal concentration is 0.24 mg/mL. The invention provides the inhibition effect of the sanguinarine on the multi-drug-resistant enterobacter horbiae, and the sanguinarine has wide application value in the fields of medicines and the like.